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ABSTRACT
The p53 and NFκB sequence-specific transcription factors play crucial roles 
in cell proliferation and survival with critical, even if typically opposite, effects 
on cancer progression. To investigate a possible crosstalk between p53 and NFκB 
driven by chemotherapy-induced responses in the context of an inflammatory 
microenvironment, we performed a proof of concept study using MCF7 cells. 
Transcriptome analyses upon single or combined treatments with doxorubicin 
(Doxo, 1.5μM) and the NFκB inducer TNF-alpha (TNFα, 5ng/ml) revealed 432 up-
regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFα 
treatment. 239 up-regulated and 161 repressed genes were synergistically regulated 
by the double treatment. Annotation and pathway analyses of Doxo+TNFα selectively  
up-regulated genes indicated strong enrichment for cell migration terms. A panel 
of genes was examined by qPCR coupled to p53 activation by Doxo, 5-Fluoruracil 
and Nutlin-3a, or to p53 or NFκB inhibition. Transcriptome data were confirmed for 
12 of 15 selected genes and seven (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were synergistically up-regulated after Doxo+TNFα and dependent both on p53 and 
NFκB. Migration assays consistently showed an increase in motility for MCF7 cells 
upon Doxo+TNFα. A signature of 29 Doxo+TNFα highly synergistic genes exhibited 
prognostic value for luminal breast cancer patients, with adverse outcome correlating 
with higher relative expression. We propose that the crosstalk between p53 and NFκB 
can lead to the activation of specific gene expression programs that may impact on 
cancer phenotypes and potentially modify the efficacy of cancer therapy.
INTRODUCTION
Cancer cells are continuously exposed to a number 
of signaling cues that reflect the distinct nature of the 
microenvironment at primary tumor site, metastastic 
lesions and potentially also during circulation in the blood 
stream [1–4]. Therapeutic intervention strategies can 
result in acute changes in microenvironment signaling, 
acting also through non-transformed cellular components 
resident at the primary tumor site [3, 5]. Cellular responses 
to changes in the microenvironment requires coordinated 
activation of sequence-specific transcription factors [6], 
among which NFκB and p53 have a prominent role and 
often opposing functions [7].
The p53 tumor suppressor gene is activated in 
response to a large number of cellular stress signals, 
including genotoxic stress, carbon and oxygen 
deficiencies, excessive proliferation signals [8, 9]. 
There are >150 established p53 target genes that link 
p53 to many different biological outcomes [10–14]. 
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The NFκB family of sequence-specific transcription factors 
consists of essential regulators of immune, inflammatory, 
proliferative and apoptotic responses [15], and their 
activation generally results in the onset of pro-survival 
signals [16]. The most common form of the NFκB complexes 
is the p50/RELA (p65) heterodimer. p53 and NFκB 
activation occurs simultaneously in response to diverse 
stress conditions, including genotoxic stress and NFκB 
proteins are frequently de-regulated in cancer, resulting in 
constitutive activation [17]. Competition between p53 and 
NFκB for a common limiting cofactor such as p300 can 
result in mutual inhibition [17, 18]. However, examples of 
positive interactions have also been reported. For example, 
it was shown that p65 can induce the p53 target gene p21 by 
direct binding to its promoter [19] and participates in p53-
dependent apoptosis [20]. Several human Toll-like receptors 
(TLRs), whose signaling leads to NFκB activation [21], 
were identified as direct p53 target genes both in cancer cells 
and primary cells [22] and it was demonstrated that p53 and 
NFκB can cooperate in the activation of pro-inflammatory 
genes in primary human monocytes and macrophages [23].
To investigate more globally the transcriptional 
crosstalk between p53 and NFκB we performed a proof 
of concept study using breast cancer-derived MCF7 
cells treated with Doxorubicin, Tumor Necrosis Factor 
alpha (TNFα) and a combination of the two compounds 
(Doxo+TNFα). Our results demonstrated a synergistic 
interaction between p53 and NFκB transcription factors, 
which can lead to the reprogramming of cell fate and 
enhanced migratory potential. Seven genes (PLK3, 
LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were established as synergistically up-regulated after 
Doxo+TNFα and dependent both on p53 and NFκB. A 29-
gene signature of highly synergistic genes up-regulated 
by Doxo+TNFα appeared to have prognostic value in a 
cohort of luminal breast cancer patients [24].
RESULTS
Striking transcriptome changes upon the 
combination of Doxorubicin and TNFα treatment 
of MCF7 cells
We first investigated the potential crosstalk between 
Doxorubicin (Doxo) and TNFα treatment using gene 
reporter assays in the human breast adenocarcinoma-
derived MCF7 cells (Figure S1A). p53-dependent 
responsiveness of the P21 and MDM2 promoter plasmid 
constructs was observed following Doxo treatment and 
confirmed by p53 silencing. The transactivation of the 
P21 and MDM2 constructs was reduced upon addition 
of TNFα to Doxo, suggesting possible inhibition of p53 
activity by NFκB. Mutual inhibition of the p53 and p65/
RELA proteins has been previously shown on p21 [17], 
while both inhibition and cooperation were reported at the 
BAX gene [18, 20]. However, this effect was not observed 
at the level of the endogenous P21 and MDM2 genes 
(Figure S1B), which showed similar level of activation 
in response to either Doxo alone or Doxo+TNFα. An 
NFκB reporter construct was responsive to both Doxo and 
TNFα as single treatments and showed a strong increase 
following the double treatment that was unaffected by 
p53 silencing. On the contrary, the endogenous TNFα 
and MCP1 NFκB target genes were weakly responsive 
to Doxo alone, highly induced by TNFα treatment, 
and showed intermediate induction levels upon double 
treatment. Hence, canonical p53 or NFκB target genes 
did not exhibit synergistic transcriptional responses to the 
combined treatment with doxorubicin and TNFα.
Next we performed a genome-wide transcriptome 
analysis after Doxo, TNFα, or the combination of the 
two compounds using the Agilent 4 × 44k array and 
single color labeling. Differentially expressed genes 
(DEGs) were selected based on rank product test, 
setting a threshold of 0.05 on the percentage of false 
positives (pfp) and a threshold of 2 on the absolute log2 
fold changes. The double treatment more than doubled 
the number of DEGs (Figure 1). The vast majority 
of DEGs resulting from the single treatments were 
also differentially expressed in the double treatment. 
Gene Ontology (GO) as well as pathway and upstream 
regulators analyses (DAVID, http://david.abcc.ncifcrf.
gov/; IPA, http://www.ingenuity.com/) confirmed 
activation of p53 signaling upon Doxo treatment as 
most significant pathway, and apoptosis induction 
as the most significantly enriched GO terms among 
up-regulated DEGs (Figure 1A-C). TNFα treatment 
also resulted in gene annotation terms consistent with 
NFκB activation, such as regulation of T cell activation. 
The gene annotation of DEGs resulting from the double 
treatment was enriched for terms typical of the two 
single treatments (e.g. T cell activation and apoptosis 
regulation among the up-regulated DEGs). TP53 as an 
upstream regulator was less significant in the double 
treatment compared to the Doxo single treatment, while 
p65/RELA, NFKBIA, IRF7 and STAT1 appeared to 
be even more enriched in the double treatment compared 
to TNFα single treatment (Figure 1B). The double 
treatment not only led to a higher number of DEGs, but 
resulted in quantitative differences in gene expression 
levels compared to the single treatments. We applied a 
rigorous filter and identified 212 repressed, 361 induced 
DEGs that were synergistically regulated by the double 
treatment Doxo+TNFα (see Methods) (Figure 1D). 
Notably, this subgroup of up-regulated DEGs was 
enriched for cell migration GO biological process 
along with the expected canonical terms for p53 and 
NFκB. Collectively, our systematic analysis indicates 
a vast network of genes that can be mutually affected 
by combined activation of p53- and NFκB-dependent 
responses.
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Doxorubicin + TNFα transcriptional synergy 
identifies new direct p53 and NFκB target genes
We selected fifteen genes for validation experiments 
based on (a) statistical analysis of synergistic up-regulated 
DEGs, (b) prior knowledge on direct regulation by either 
p53 or NFκB, (c) availability of ChIP-seq data for both 
transcription factors, and (d) gene functions in relation to 
cancer biology. The selected list contains genes encoding 
players of the control of various cellular processes, 
e.g. cell proliferation (PLK3, DUSP5, PLAU, GBX2, 
ETV7, EDN2), apoptosis (TNFRSF10B, UNC5B), 
inflammation (LAMP3, EGR2), development (GBX2, 
SOX9, NPPC, FOXC1) and cell migration (SNAI1, 
PLAU, UNC5B, NTN1, EDN2).
For twelve of the 15 genes we confirmed a 
synergistic response to the Doxo+TNFα treatment by 
qPCR (Figure 2A). Most of them were independently 
reported as putative targets of either p53, p65 or both 
according to published ChIP-seq data (for p65, http://
genome.ucsc.edu/ENCODE) [14, 25]. A potential direct 
contribution of NFκB on the observed gene expression 
Figure 1: A vast array of genes responds selectively to Doxorubicin and TNFα in MCF7 cells. (A) Number of DEGs 
identified after single or combined treatment (see Methods for statistical filters). Most significant gene ontology terms of down- or 
up-regulated DEGs, according to DAVID (http://david.abcc.ncifcrf.gov). (B) Predicted upstream regulators of the DEGs for the indicated 
treatments, according to IPA (IPA, http://www.ingenuity.com). The color code reflects the enrichment or depletion of the listed transcription 
factors targeting the DEGs from the array analysis. (C) Statistically relevant pathways predicted to be modulated in response to the 
indicated treatments according to IPA. (D) Number of DEGs that are synergistically regulated by the double treatment according to two 
different statistical filters (see Materials and Methods). The most significant gene ontology terms are also indicated.
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changes was evaluates using the small molecule 
inhibitor BAY 11–7082 (BAY) used as single agent or in 
combination with Doxo or/and TNFα (Figure 2B). Eight 
of the twelve validated synergistic DEGs were tested 
and for five of them BAY markedly inhibited the effect 
of Doxo+TNFα, or of TNFα alone. TNFα treatment led 
to higher levels of nuclear p65, while Doxo alone or in 
the combined treatment did not significantly impact p65 
nuclear protein levels. BAY treatment led to a slight 
reduction of p65 nuclear levels, which was paralleled 
by an increase in the cytoplasm (Figure 2C). p53 protein 
levels were induced to similar levels by the different 
treatment combinations (Figure S2).
The five genes that showed more convincing 
p65 dependence on the synergistic response to 
Doxo+TNFα (PLK3, NTN1, UNC5B, ETV7, LAMP3) 
were investigated more deeply to establish a direct role 
of wild type p53 in their transcription. MCF7 cells were 
treated with the chemotherapeutic agent 5-Fluorouracil 
(5FU) or with the MDM2 inhibitor Nutlin-3a, alone or in 
combination with TNFα. Both p53-inducing molecules 
were at least additive with TNFα in the responsiveness 
of the five genes (Figure 2D). Although the magnitude 
of the synergistic response was higher with Doxo, the 
fact that three different p53-activating treatments led 
to up-regulation of these five genes strongly suggested 
a direct role of p53. We next employed an MCF7 clone 
with stable knock-down of p53 and the HCT116 p53-/- 
cell line, to further establish p53-dependence of the five 
genes expression upon Doxo treatment. Matched MCF7 
vector and HCT116 p53+/+ were used as a comparison 
(Figure 2E, F). Invariably, Doxo responsiveness was 
strongly reduced in the p53-defective cells. Previous 
reports in the literature demonstrated or suggested p53-
dependent regulation of PLK3, NTN1 and UNC5B. Our 
results confirm those findings and establish, for the first 
time, the possibility of synergistic regulation by NFκB. 
PLK3, a polo-like kinase, is an important regulator of 
the cell cycle and it is involved in the control of hypoxia 
signaling pathway [26]. NTN1 is ligand for both DCC1 
and UNC5B receptors whose signaling can potentially 
modulate p53 activity, impacting on the decision between 
cell survival and cell death [27]. LAMP3 is a lysosomal 
membrane associated protein important in dendritic 
cells and potentially involved in tumor invasion [28], 
while ETV7 is a transcription factor associated to cell 
proliferation and tumorigenesis [29].
Given the lack of definitive evidence for LAMP3 
and ETV7 being direct p53 targets and since our finding 
of synergistic responsiveness, we examined p53 and 
(Continued )
Figure 2: p53- and p65-dependent up-regulation of selected synergistic DEGs. (A) Twelve out of fifteen selected synergistic 
DEGs were validated by qPCR. Plotted are the average fold change relative to the mock condition and three reference genes (GAPDH, 
B2M, ACTB) and the standard deviations of three biological replicates. “^” marks genes responding in synergistic manner to the double 
treatment. p53 and p65 occupancy data from available ChIP-seq datasets are summarized below each gene name. (B) Impact of the NFκB 
inhibitor BAY 11-7082 on the synergistic gene expression response plotted as in panel A. “*” Significant inhibition of by BAY when 
combined to Doxo + TNFα (t-test, p<0.01). NPPC and SNAI1 were also tested but their expression levels were not affected by BAY 
treatment. 
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p65 occupancy in MCF7 cells treated with Doxo or TNFα 
(Figure 3). p53 occupancy was detected both for ETV7 
and LAMP3 as well as for the positive control P21, in 
Doxo treated cells. For ETV7 p53 occupancy appeared 
to increase also after TNFα treatment. P21 was the only 
target for which p53 appeared to be bound also in the 
mock condition, a result consistent with previous data 
[30]. p53 occupancy levels were not distinguishable 
between Doxo and Doxo+TNFα treatment.
Both LAMP3 and ETV7 exhibited p65 occupancy in 
TNFα treated cells, although to a lower extent compared 
to the positive control MCP1. For the three promoter 
regions, occupancy was increased also by Doxo treatment 
alone, but no additive effect of the double treatment was 
apparent, except for a trend with LAMP3. On the contrary 
lower occupancy at MCP1 was detected in double treated 
cells. This latter result is consistent with the MCP1 mRNA 
expression changes (Figure S1B).
Hence, we identified genes whose expression is 
co-regulated by Doxo and TNFα. The gene expression 
studies conducted with different p53-activating molecules, 
the use of cells lines with different p53 status, and the 
chromatin immune-precipitation studies collectively 
established a direct role for p53 and p65 on the 
transcriptional regulation of PLK3, NTN1, ETV7, UNC5B 
and LAMP3. However, we did not find a direct correlation 
between occupancy levels at predicted promoter binding 
sites and gene expression changes.
Figure 2: (C) p65 nuclear (NE) and cytoplasmic (CE) relative protein levels under the different treatments used in panel B. M = mock; 
D = Doxo; T = TNFα; B = BAY. Proteins were fractionated as described in Materials and Methods. GAPDH and histone 3 (H3) served 
as controls for cytoplasmic and nuclear fraction respectively. As controls, a cytoplasmic mock fraction sample (CE) is loaded together 
with the nuclear proteins and vice versa a nuclear mock sample (NE) in included in the cytoplasmic blot. (D) 5-fluorouracil and Nutlin-3a 
induced expression of 5 selected DEGs alone or in combination with TNFα. Results were obtained and are plotted as in A. (E), (F) The 
relative expression of the 5 selected genes shown in panel C was tested in doxorubicin treated matched cell lines differing for p53 status 
(MCF7 vector and shp53, D; HCT116 p53+/+ and p53-/-, E).
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Doxorubicin + TNFα treatment enhances the 
migration potential of MCF7 cells
Both the gene ontology enrichments of synergistic 
DEGs and the known function of the fifteen genes chosen 
for validation suggested the possible activation of gene 
expression programs influencing cell motility, epithelial 
mesenchymal transition (EMT) or even stem-like 
phenotypes. Projected to an in vivo context, the crosstalk 
of signals present in an inflammatory microenvironment 
could have a negative impact on the efficacy of 
chemotherapy, possibly by enhancing tumor cell plasticity. 
To begin exploring this hypothesis, we investigated 
migration and invasion potential of MCF7 cells treated 
with Doxo, TNFα or both. Three different experimental 
approaches consisting in real-time cell migration analysis 
(Figure 4A), transwell migration test (Figure 4B) and 
wound healing assay (Figure 4D) consistently showed 
higher migration potential of double-treated MCF7 cells, 
while the invasion phenotype was unaffected by all three 
types of treatment (Figure 4C).
Several studies suggest that EMT not only enhances 
the motility and invasiveness of cancer cells, but also 
provides additional aggressive features such as stemness 
and therapeutic resistance [31]. Indeed, several of the 15 
synergistic DEGs we validated are directly or indirectly 
associated with acquisition of stem-like phenotypes in 
normal or cancer cells, particularly SNAI1 [32, 33], 
SOX9 [34] and GBX2 [35]. Different lines of evidence 
indicate that breast cancer stem cells (BCSCs) display 
increased cell motility, invasion, and overexpress genes 
that promote metastasis [36] and can be traced by CD44+/
CD24-/low surface marker expression [37]. We asked if 
the Doxo+TNFα treatment could enhance the stem-like 
subpopulation of the MCF7 cell line (Figure 4E). FACS 
analysis showed that the CD44+/CD24- subpopulation 
virtually disappeared after all treatments. Therefore, the 
higher motility observed upon double treatment cannot be 
directly related to the expression of these surface markers, 
hence to putative stem-like features.
Prognostic value of Doxorubicin + TNFα 
synergistic DEGs
Since luminal type breast cancer, of which MCF7 
is considered as a model, frequently retains wild type 
p53 and NFκB responsiveness, we asked if Doxo+TNFα 
synergistic DEGs could be endowed with prognostic 
significance. Up-regulated DEGs were further filtered 
by selecting genes that were strongly responsive to the 
double treatment but minimally responsive to the single 
ones (see Materials and Methods). A signature list of 
Figure 3: Occupancy analysis establishes ETV7 and LAMP3 as direct p65 and/or p53 target genes. (A) Relative 
quantification of immune-precipitated gene fractions by qPCR from MCF7 cells subjected to Doxo or TNFα single treatments and to the 
double treatment. The antibodies used for the immune-precipitations are listed. P21 was used as positive control, while ACTB was used 
as a negative control. Plotted are the average percentages relative to input signals. Error bars represent the standard errors of at least three 
biological replicates. (B) as in A, but probing p65 occupancy. MCP1 was used as positive control. The IgG antibody controls were anti-
mouse (A) or anti-rabbit (B) to match the specific primary antibodies. (C) The position of the primers used for the qPCR and the location 
of predicted p53 and p65 binding sites in the ETV7 and LAMP3 genes are depicted.
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Figure 4: Doxo+TNFα leads to enhanced MCF7 motility but ablates the stem-like side population. (A) Real-time migration 
assays examined by xCELLigence. Plotted are the average results of four biological repeats. Cell Index is proportional to the number of cells 
migrating through a hole in the culture plate. The treatments relative to the different curves are indicated. (B) Relative transwell migration 
values quantified by a fluorescence readout (see Materials and Methods). Average and standard deviation of triplicate biological replicates are 
presented. The applied treatments are listed on the x-axis. (C) As for B, but measuring the invasion potential of MCF7. (D) Images of a wound 
healing assay obtained at T0 or T24. Composite (3×3) images were acquired using an automated Zeiss microscope and the AxioVision3.1 
software. (E) Cell sorting results based on intensity of CD44 and CD24 surface markers on 30000 cells. Q1 individuates the CD44+/CD24-(low) 
cells, considered as stem-like. The percentages in the four quadrants after the various treatments are presented in the table.
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29 genes (DT29) was generated (Figure 5A) and used to 
interrogate clinical data using the KM plotter tool [38]. 
Interestingly, breast cancer patients with luminal type A 
diagnosis who underwent chemotherapy and exhibited 
higher relative expression of DT29 genes showed poorer 
prognosis (Figure 5B). The same was true for luminal A 
patients with lymph node infiltration or luminal A grade 2 
(Figure 5C, D).
Analysis of Doxorubicin and TNFα crosstalk in 
lung cancer-derived and HUVEC cells
We extended our analysis to another pair of cancer 
cell lines that differ for p53 status. A549 (p53 wild type) 
and H1299 (p53 null) lung cancer derived cells were 
treated with Doxo or/and TNFα or/and BAY. Expression 
of PLK3, NTN1, ETV7, UNC5B and LAMP3 was 
measured by qPCR (Figure 6A-E). The impact of the 
various treatments on p65 nuclear and cytoplasmic, p53 
and p21 protein levels was also evaluated (Figure 6F, 6G). 
In the p53 null H1299 cells the relative expression changes 
of all the genes was invariably much lower compared to 
A549 cells. However, NTN1 was weakly TNFα inducible 
and ETV7 was weakly Doxo+TNFα responsive. Instead in 
A459 cells NTN1, ETV7 and LAMP3 were synergistically 
up-regulated by Doxo+TNFα, while PLK3 and UNC5B 
were additive. The magnitude of induction upon Doxo 
was often one order of magnitude higher compared 
to TNFα alone. Transient transfection assays with the 
κB luciferase reporter construct were performed using 
different concentrations of TNFα or BAY (Figure S3). 
Based on the results, 10ng/ml TNFα and/or 20μM BAY 
were chosen for the qPCR experiments, although the 
reduction of TNFα-induced reporter activity was modest, 
albeit significant. At the endogenous gene level in A549 
cells we did not observe the inhibitory effect of BAY on 
either TNFα-induced changes or Doxo+TNFα, with the 
possible exception of UNC5B (Figure 6A-E). However, 
BAY treatment reduced the Doxo responsiveness of these 
genes, which might be dependent on its effect on the 
activation of NFκB by endogenous production of TNFα. 
In the p53 wild type A549 cells, p53 and p21 protein 
levels were induced by Doxo and not affected by the 
treatment with TNFα. Total p65 levels were unaffected 
by all treatments in both cell lines (Figure 6F). Nuclear 
p65 protein levels were increased in response to TNFα or 
Figure 5: Prognostic significance of a 29-gene list of synergistic Doxo+TNFα DEGs. (A) Top list of 29 genes (DT-29) 
exhibiting minimal responsiveness to Doxo or TNFα as single agents, but strong synergy upon combined treatment. A heat map view of 
the gene expression results is presented (see Materials Methods for statistical filters). Occupancy of both for p65 and p53 in the vicinity 
of the transcription start sites of these genes has been summarized from ChIP-seq data available in the literature. (B-E) Kaplan-Meier 
plots stratifying a breast cancer patient cohort based on the relative expression of the DT-29 gene list and relapse free survival. Graphs 
were generated with the KM-plotter tool (ref). Patients’ numbers are listed below the graph. Hazardous Ratio and the statistical analysis is 
reported for selected patients subgroups: (B) luminal A patients who underwent chemotherapy treatment (n = 111); (C) luminal A patients 
with a Grade 2 cancer at diagnosis (n = 385); (D) luminal A patients with lymph node infiltration at diagnosis (n = 447) and (E) the entire 
cohort of luminal A patients (n = 1509). Patients with a diagnosis of Luminal A breast cancer subtype were selected as the p53 status is not 
available in KM plotter, but this subgroup of breast cancer is expected to be strongly enriched for cases retaining wild type p53 protein.
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Figure 6: PLK3, NTN1, ETV7, UNC5B and LAMP3 responsiveness in lung cancer cell lines. (A-E) Relative fold change 
expression of the indicated genes and after the listed treatments in A549 (p53 wild type) and H1299 (p53 null) cells, measured by qPCR. 
Average and standard deviations of three biological replicates are presented. (F) Western blot of total p65, p53 and the p53 target p21. 
GAPDH was used as loading control. (G) Western blot of nuclear and cytoplasmic protein fractions were performed as for Figure 2C.
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Doxo+TNFα in both A549 and H1299 cells (Figure 6G). 
Interestingly, BAY treatment alone or in combination led 
to a reduction in p65 nuclear accumulation (Figure 6G).
HUVEC primary cells were also subjected to Doxo 
and TNFα single or double treatment and the expression 
of the same panel of five genes was tested by qPCR 
(Figure S4). Results among biological repeats varied, but 
in the majority of tests, all genes with the exception of 
LAMP3 were Doxo responsive; NTN1 and ETV7 were 
also TNFα responsive. No synergistic up-regulation by the 
double treatment could be consistently established. p53 
and p65 protein levels confirmed i) the activation of p53, 
with a similar level of p53 protein in the double treatment, 
and ii) the p65 proficiency of this cell line.
DISCUSSION
Wild type p53 functions are intricately related to 
multiple tumor suppressor pathways, primarily acting 
in cell autonomous manner to restrain cell proliferation 
and including cell death and senescence in response 
to genotoxic and many other types of cellular stresses 
[8, 9]. Furthermore, p53 also contributes to modulate 
the microenvironment in a non-cell autonomous 
manner [39]. p53 has also been linked to inhibition of 
EMT, for example through an indirect stimulation of 
E-cadherin expression [40]. At the same time, paracrine 
signaling in mice triggered by Doxorubicin were found 
to stimulate EMT and metastatic potential of cancer 
cells, in part through NFκB activation [3]. Many studies 
have highlighted the potential contribution of NFκB-
induced signaling in the acquisition of cancer cell traits 
conducive to chemoresistance and higher metastasis 
risk [2] [41]. While, the canonical functions of p53 and 
NFκB are consistent with the co-occurrence of p53 
inactivation and NFκB hyper-activation that is frequent in 
cancer [7], recent studies provided examples of positive 
cooperation between p53 and NFκB that would occur 
in specific cell types, such as antigen presenting cells or 
macrophages, and contribute to physiological responses, 
such as for example in the process of innate immunity and 
inflammation [12, 22, 23, 42].
Here we modeled the impact of a first line 
chemotherapeutic drug leading to genotoxic stress and 
p53 activation, using exposure to the immune cytokine and 
NFκB activator molecule TNFα as a variable, mimicking 
the effect of an inflammatory microenvironment. We 
used transcriptome analysis as primary endpoint and 
uncovered a vast network of differentially expressed 
genes that selectively responds to combined treatment 
with Doxorubicin and TNFα. Furthermore, genes that 
were synergistically up-regulated by both treatments 
appeared to endow cells with higher motility potential 
in vitro. Analyses of the annotated gene functions related 
to the aforementioned genes also revealed the possibility 
of an induced epithelial mesenchymal transition upon 
combination of the treatments. For example, SNAI1 
appeared to be regulated in more than additive manner 
by the double treatment, as well as LAMP3, a lysosomal 
protein previously associated with metastasis risk [28, 
43]. Multiple cytokines and secreted factors, including 
IL6, IL17, IL15 and its receptor, S100A8 and S100A9, 
CXCL12 and several Serpins were also identified as 
synergistic DEGs (Table S1). The presence of S100A8, 
S100A9 and CXCL12 among synergistic DEGs raises 
the possibility that, unlike the case of the triple negative 
cell line MDA-MB-231 for which S100A8-mediated 
signaling appeared to require heterotypic cell interactions 
[3] contributing to metastasis potential, in MCF7 cells 
this signaling could become homotypic or even autocrine. 
A marked difference in secreted factors and associated 
signaling among MDA and MCF7 cells was elegantly 
shown in recent studies [4].
A direct contribution of p65/RELA and p53 
in the observed gene expression changes elicited by 
Doxorubicin and TNFα was inferred for some of the 
synergistic DEGs by modulating pharmacologically or 
genetically p65 or p53 activities. However, we cannot 
exclude at this stage a (Doxo+TNFα)-dependent, but 
p53- or NFκB- independent gene expression changes. 
For example, NFkB can functionally interact with 
AP-1 [44–46] or ER [47], which in turn can modulate 
p53-dependent responses [48] [49] [50].
Among the most synergistic genes, 29 appear to 
be prognostic in luminal A breast cancer patients who 
underwent chemotherapy, where their higher expression 
correlated with adverse outcome. The majority of luminal 
A breast cancers are wild type for p53 [51], although data 
is not available to stratify patients for p53 status in the 
KM plotter tool [24]. Based on available ChIP-seq data 
[14, 25, 52, 53], 20 of these 29 genes are putative targets 
of either p53 or p65 and 10 of them are putative targets of 
both factors (Figure 5). This result raises the possibility 
of an unexpected negative outcome of chemotherapy in 
the context of an inflammatory microenvironment. The 
prognostic significance of this gene signature needs 
in-depth evaluation in independent patients cohorts. If 
confirmed, the results would further support the value 
of combining treatments activating p53 and repressing 
NFκB [7].
Given that the crosstalk between Doxorubicin 
and TNFα and the interplay between p53 and NFκB 
would occur in cells residing or infiltrating the tumor 
microenvironment, the ultimate in vivo outcome of these 
functional interactions may vary and cannot be directly 
predicted from our study using a pure culture of MCF7 
cells in vitro. Here we have explored Doxo+TNFα 
impact on HUVEC cells and also on a p53 wild type lung 
adenocarcinoma-derived cancer cell line. Although limited 
by the number of genes tested, the results suggest that a 
positive crosstalk between Doxorubicin and TNFα can 
be a general characteristic of different cell types and is 
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at least in part p53-dependent, based on the results with a 
p53 null lung cancer cell line. Furthermore, while we have 
addressed here the functional interactions between two 
small molecules, cells are constantly exposed to a complex 
milieu of signaling factors. However, both p53 and NFκB 
are master regulators, often contributing a dominant trait 
in gene expression changes to their target genes. Nuclear 
receptors, including Estrogen Receptors (ERs) can also 
modulate NFκB as well as p53 functions [54–56] and 
have critical roles in breast cancer etiology. We also 
explored the impact of ER function in the transcriptional 
programs responding to Doxorubicin and TNFα exposure, 
using estrogen-depleted culture conditions and adding 
17β-estradiol (10-9M, E2) as variable (Table S2 and GSE 
24065). However, the combination of E2 to Doxo and 
TNFα resulted only in 15 and 11 selective up- and down-
regulated DEGs, respectively (Table S3). A hierarchical 
cluster analysis of all the treatments confirmed graphically 
the large difference between TNFα- and Doxo-induced 
transcriptomes and also the significant impact of TNFα 
when combined to Doxo, while E2 had a minor effect both 
in the combination with Doxo and with Doxo + TNFα 
(Figure S5).
With this study we established an example of 
positive cooperation between p53 and NFκB, in the 
context of the responses of an epithelial cancer cell to 
standard chemotherapy but in the presence of active 
signaling by a pleiotropic inflammatory cytokine, such as 
TNFα. A signature gene of the consequent transcriptional 
reprogramming appears to be prognostic in breast cancer 
patients. Associated gene functions indicate the potential 
acquisition of enhanced cell plasticity and motility and 
provide a rationale to investigating mechanisms resulting 
in acquired chemoresistance, particularly for luminal A 
breast cancer, but potentially with general implication 
for p53 wild type tumors of different tissue types, and 
for overcoming such resistance by targeting NFκB. The 
unexpected positive crosstalk between p53 and NFκB 
emerging from our and other very recent studies [23] 
may represent an evolutionary consequence of anti-
viral and infection responses towards which NFκB is 
an established master regulator [57], but the p53 and 
p73 family member are emerging as important/critical 
contributors [42, 58, 59].
MATERIALS AND METHODS
Cell lines and culture conditions
MCF7 (p53 wild type, expressing p65 and positive 
for ERs) and HUVEC (Human Umbilical Vein Endothelial 
Cells) cells were obtained from ICLC (Genoa, Italy), while 
A549 from ATCC (Manassas, VA, USA). H1299 cells were 
a gift of Dr. Resnick’s laboratory (NIEHS, NIH, RTP, NC, 
USA); HCT116 p53+/+ and p53-/- of Dr. Vogelstein’s (John 
Hopkins Kimmel Cancer Center, Baltimore, MD, USA). 
MCF7-shp53 or control MCF7-vector cells were provided 
by Dr. Agami (Netherlands Cancer Institute, Amsterdam, 
The Netherlands). Cells were cultured in DMEM or 
RPMI media supplemented with 10% FBS, or Medium 
199 (Lonza Milan, Italy) supplemented with 50 units/
ml Low Serum Growth Supplements (Life Technologies, 
Milan, Italy) in the case of HUVEC cells that were also 
cultured on 0.1% gelatin pre-coated plastics. Media were 
supplemented by 2mM L-Glutamine and 1XPenicillin/
Streptomycin mixture (Pen/Strep), and Puromycin (0.5 μg/
mL) in the case of MCF7-shp53 and –vector cells. When 
appropriate, cells were maintained in DMEM without 
Phenol Red (Lonza) supplemented with Charcoal/Dextran 
treated FBS (Hyclone, GE Healthcare, South Logan, 
UT, USA).
Drug treatments
Doxorubicin (Doxo, 1.5 μM), 5-Fluorouracil (5FU, 
375 μM), Nutlin-3a (10 μM) were used to stabilize p53 
protein. When needed TNFα (5ng/ml in MCF7 and 10ng/
ml in H1299, A549 and HUVEC cells –based on dose-
response tests with gene reporter assays) or BAY11-7082 
(10μM or 20μM in H1299 and A549) were added to the 
culture medium. All compounds were from Sigma-Aldrich 
(Milan, Italy).
Microarray experiment and data analysis
Total RNA was extracted from 4 biological 
replicates using the Agilent Total RNA Isolation Mini Kit 
(Agilent Technologies, Santa Clara, CA, USA). Samples 
with RNA Integrity Number (RIN) above 9 (Agilent 2100 
BioAnalyzer) were processed. Details are provided with 
the Gene Expression Omnibus (GEO) (www.ncbi.nlm.
nih.gov/geo) submission (GSE24065) and in [56]. The 
output of Feature Extraction (Agilent standard protocol 
GE1_107_Sep09) was analyzed with the R software for 
statistical computing and the Bioconductor library of 
biostatistical packages. Probes with low signals were 
removed in order to filter out the unexpressed genes 
and keep only probes with acceptable signals in most 
of the replicates. Signal intensities across arrays were 
normalized by quantile normalization. Signal intensities 
from probes associated with the same gene were averaged. 
This procedure resulted in quantitative signals for 14095 
HGNC genes. To identify potential target genes of 
Doxorubicin and TNFα, we compared the signals after 
the double treatment (Doxo+TNFα) and the two single 
treatments relative to the untreated control (mock). 
DEGs were selected applying a statistical test based on 
rank products implemented in RankProd Bioconductor 
package, setting a threshold of 0.05 on the percentage of 
false positives (pfp) and a threshold of 2 on the absolute 
log2 fold changes [60]. Every treatment was compared to 
the mock condition (Table S1, S2 and Figure S5).
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To select genes with synergistic effect, i.e. genes 
whose expression variations were more than additive in 
the double treatment with respect to single treatments, a 
further comparison between the double treatment samples 
and all the remaining samples (single treatments and 
control samples) was performed (double treatment vs all). 
Synergistic DEGs were selected applying an additional 
pfp filter (pfp<0.005) derived from this comparison, to 
the list of DEGs resulting from the “double treatment 
vs mock” comparison. A more stringent criterion was 
obtained by calculating the synergistic effect (SE) of 
the double treatment as the observed difference between 
the fold change of the double treatment and the sum of the 
fold changes of the single treatments (SE=log2 FC double 
treatment – (log2 FC Doxorubicin + log2 FC TNFα). 
We filtered genes with SE>0 for up-regulated DEGs, 
SE<0 for down-regulated genes (Figure 1). To select 
genes where the up-regulation contribution of each single 
treatment was low respect to the up-regulation of the 
double treatment, the ratio of the single/double treatments 
was calculated, applying a 0.25 filter on them (FC 
Doxorubicin/FC double treatment <0.25 and FC TNFα/
FC double treatment <0.25) (see Table S1, S2).
RNA isolation and quantitative qPCR
Total RNA was extracted using Qiagen RNeasy Kit 
(Qiagen). cDNA was converted from 1 µg of RNA using 
M-MuLV reverse transcritptase and RevertAid cDNA 
Synthesis kit (ThermoFisher, Milan, Italy). qPCR was 
performed on a Bio-Rad CFX384 (Bio-Rad, Milan, Italy). 
TaqMan gene expression assays (Applied Biosystems, Life 
Technologies) and Probe MasterMix (Kapa Biosystems, 
Resnova, Rome, Italy) were used starting with 25ng of 
cDNA as previously described [56, 61]. GAPDH, B2M or 
ACTB served as reference genes.
Western blot
Protein extraction and immunodetections were 
performed as previously described [62], using ECL Select 
detection reagent (GE Healthcare) and anti-p53 (DO-1) 
anti-RelA/p65 (C-20) anti- p21 (C19), anti-GAPDH (6C5) 
(Santa Cruz Biotechnology, Heidelberg, Germany). When 
appropriate, nuclear and cytoplasmic fractionation was 
performed. MCF7, A549 and H1299 cell lines were seeded 
on 100mm Petri dishes and treated at 80% confluence 
with Doxo, TNFα, BAY or the combination of the drugs 
for 16 hours. Cells were harvested and cytoplasmic and 
nuclear proteins were extracted using NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Pierce, ThermoFisher 
Scientific), following the instructions provided by the 
manufacturer. 20 μg of nuclear and cytoplasmic extracts 
were loaded on a 12% poly-acrylamide gel and transferred 
to nitrocellulose membranes. Antibodies used for detection 
were: anti-Histone H3 (clone #: ab1791, AbCam, Milan, 
Italy) and anti-Lamin A/C (clone #: 2032, Cell Signaling, 
Milan, Italy) used as nuclear loading control, and anti-
GAPDH used as cytoplasmic loading control.
Chromatin immunoprecipitation assay
We used previously described protocols [63, 64]. 
The following antibodies were used: anti-p53 (DO-1), 
anti-p65 (C-20) and IgG (sc-2025 or sc-2027) (Santa Cruz 
Biotechnology). ChIP-qPCR experiments were performed 
using Sybr MasterMix (Kapa Biosystems) and 2 μl of 
enriched DNA. Results were analyzed by the comparative 
Ct method (ΔCt) and normalized as % of input. Regions 
in the promoter of GAPDH or ACTB and p21 or 
MCP1 genes served as negative and positive controls, 
respectively. Primers were selected using Primer 3 
(http://primer3.ut.ee/).
Migration and wound healing assays
The migration potential of MCF7 cells was 
monitored by a real-time technique using the 
xCELLigence Instrument (Acea Biosciences, Euroclone) 
and CIM-16 plates, following manufacturer’s instructions. 
Prior to the analysis, cells were grown in estrogen-free 
medium for two days and left untreated (mock) or treated 
with Doxo, TNFα or the combination. 16 hours after 
the treatments, cells were detached and added to the top 
chamber in serum-free medium. Migration was detected 
every 10 minutes for 24 hours. We used 0.5% and 5% 
FBS as chemo-attractant. Migration and Invasion were 
also measured by QCMTM Fluor 24-Well Cell Migration 
and Cell Invasion kits (Merck-Millipore, Milan, Italy), 
according to manufacturer’s instructions. For wound 
healing, cells were seeded in 12-well plates and treated 
with Doxo, TNFα or the combination. After 16 hours a 
scratch was introduced using a 10 μl pipette tip. Images of 
the same field were acquired immediately (T0) and after 
24 hours (T24) using an automated Zeiss microscope and 
the AxioVision3.1 software in multidimensional mode 
with mosaic (3x3) acquisition.
Flow cytometry
MCF7 cells, seeded and treated as described 
above, were washed with PBS and harvested by 0.05% 
trypsin/0.025% EDTA. The cells were washed again 
with PBS containing 2% FBS before being subjected 
to antibody binding, a combination of fluorochrome-
conjugated monoclonal antibodies against human CD44 
(APC) and CD24 (FITC) or their respective isotype 
controls (BD Biosciences, Milan, Italy) and incubated on 
ice in the dark for 30 minutes. Cells were then washed 
twice with PBS/2% FBS and resuspended in PBS. Flow 
cytometry analysis was conducted using a FACSCanto II 
instrument (BD Biosciences).
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